AbbVie’s ABBV-295 Yields Up to 9.8% Weight Loss in Phase 1 Trial
AbbVie’s ABBV-295 phase 1 study showed clinically meaningful, dose-dependent weight reductions ranging from 7.75% to 9.79% at week 12, with doses between 2 mg and 14 mg. The treatment was generally well tolerated, with mild gastrointestinal disorders as the most common adverse events.
1. Phase 1 Trial Results
In a first-in-human study, ABBV-295 achieved mean body weight reductions of 7.75% to 9.79% at week 12 across dosing cohorts from 2 mg to 14 mg, demonstrating a clear dose-response relationship in obese participants.
2. Safety and Tolerability
The investigational amylin analog was generally well tolerated, with the most frequently reported adverse events being mild gastrointestinal disorders such as nausea and diarrhea, and no serious safety signals observed.
3. Collaboration with Gubra
AbbVie executed a licensing agreement in March 2025 with Gubra A/S to develop GUB014295 (ABBV-295), leveraging Gubra’s proprietary amylin platform to expand AbbVie’s metabolic disease pipeline.
4. Strategic Implications
Positive early obesity data could strengthen AbbVie’s position in the metabolic arena and support longer-term valuation growth as the company diversifies beyond its core immunology and oncology franchises.